ProKidney (PROK) Competitors

ProKidney (NASDAQ:PROK) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Do institutionals and insiders believe in PROK or PHVS?

51.6% of ProKidney shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has better valuation & earnings, PROK or PHVS?

ProKidney has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$76K	3,065.24	-$35.47M	-$0.63	-1.26
Pharvaris	N/A	N/A	-$109.18M	-$2.68	-5.12

Does the media prefer PROK or PHVS?

In the previous week, Pharvaris had 12 more articles in the media than ProKidney. MarketBeat recorded 16 mentions for Pharvaris and 4 mentions for ProKidney. ProKidney's average media sentiment score of 0.96 beat Pharvaris' score of 0.32 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer PROK or PHVS?

Pharvaris received 28 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 66.67% of users gave Pharvaris an outperform vote while only 57.14% of users gave ProKidney an outperform vote.

Company	Underperform	Outperform
ProKidney	Outperform Votes 8 57.14%	Underperform Votes 6 42.86%
Pharvaris	Outperform Votes 36 66.67%	Underperform Votes 18 33.33%

Which has more risk and volatility, PROK or PHVS?

ProKidney has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.84, suggesting that its stock price is 384% less volatile than the S&P 500.

Do analysts rate PROK or PHVS?

ProKidney presently has a consensus target price of $5.00, indicating a potential upside of 528.22%. Pharvaris has a consensus target price of $40.50, indicating a potential upside of 195.19%. Given ProKidney's higher possible upside, equities analysts clearly believe ProKidney is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharvaris	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is PROK or PHVS more profitable?

ProKidney's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-10.24%
Pharvaris	N/A	-38.52%	-36.69%

Summary

ProKidney beats Pharvaris on 11 of the 16 factors compared between the two stocks.